Pariet 20mg 14 enteric tablets— Made in Switzerland — Free Delivery

Pariet belongs to the class of antisecretory compounds, which are chemically substituted benzimidazoles, suppresses gastric acid secretion by specifically inhibiting the h + / k + -atphase enzyme on the secretory surface of gastric parietal cells. this enzyme system is considered an acid (proton) pump, therefore pariet is classified as an inhibitor of the gastric proton pump, which blocks the final stage of gastric acid production. the preparation does not have anticholinergic activity and is not an antagonist of histamine H2-receptors. it was experimentally established that after the introduction of rabeprazole sodium into the body quickly disappears both from the blood plasma and from the gastric mucosa. rabeprazole sodium has a slightly alkaline reaction, is rapidly absorbed in the digestive tract and is concentrated in parient cells. rabeprazole sodium is converted to the active sulfenamide form by protonation and thus reacts with the available cysteine ​​residues of the proton pump.

After oral administration of 20 mg of Pariet, the antisecretory effect occurs within 1 hour and reaches a maximum after 2–4 hours. Inhibition of basal and food-stimulated secretion of gastric acid 23 hours after taking the first dose of Pariet was 62 and 82%, respectively, and the duration of this effect reached 48 hours. The inhibitory effect of Pariet on the secretion of gastric acid increases slightly during the daily intake of 1 tablet, and a stable inhibition of secretion is achieved 3 days after the start of taking this preparation. After the end of the reception of Pariet, secretory activity is normalized within 2-3 days.

Effect on serum gastrin concentration

In clinical trials, patients took 10 or 20 mg of Pariet 1 time per day for up to 12 months. During the first 2–8 weeks of therapy, the serum gastrin concentration increased, reflecting the inhibition of gastric acid secretion. The concentration of gastrin was restored to the initial level, usually within 1–2 weeks after the end of treatment. The study of biopsies of the fundus and antrum of the stomach in more than 500 patients who received Pariet or the reference preparation for up to 8 weeks did not reveal any histological changes, the severity of gastritis, the frequency of atrophic gastritis, intestinal metaplasia, and the prevalence of H. pylori infection. With long-term treatment for 36 months, more than 250 patients also showed no significant changes in the results of these studies.

Due to the special dosage form, the absorption of sodium rabeprazole occurs in the intestine. This dosage form protects rabeprazole sodium from the effects of hydrochloric acid, which breaks down this compound. It is rapidly absorbed from the intestine and its peak plasma concentrations are reached approximately 3.5 hours after ingestion of a 20 mg dose. The maximum plasma concentration and AUC of rabeprazole are linear in the dose range of 10–40 mg. The absolute bioavailability after oral administration of 20 mg (compared to intravenous administration) is about 52%, largely due to first pass metabolism through the liver. In addition, bioavailability does not increase with repeated administration of Pariet. In healthy volunteers, the plasma elimination half-life was approximately 1 hour (from 0.7 to 1.5 hours), and the total clearance was 283 ± 98 ml / min. Absorption of Parieta does not depend on food intake and time of administration of the preparation. The degree of binding of rabeprazole sodium to blood plasma proteins reaches 97%. The main metabolites detected in blood plasma are thioester and carboxylic acid, while secondary metabolites, which are detected at low concentrations, are sulfone, dimethylthioethyl, and mercapturic acid conjugate. Only the dimethyl metabolite (M3) has an insignificant antisecretory activity, but it is not detected in the blood plasma. After a single dose of 20 mg, rabeprazole is not detected in the urine in an unchanged form. Approximately 90% of the administered dose is eliminated in the urine mainly in the form of two metabolites: a conjugate of mercapturic acid and carboxylic acid; in addition, experimental studies have identified two more unidentified metabolites. The rest of the preparation  is excreted in the feces. The pharmacokinetics of rabeprazole in men and women are not different.